Riskpilot← Back to searchSign inGet full accessPharmovital ApS
APSActiveCVR 27206506Rosenkæret 11BWholesale of other food · NACE 4638Est. 20036 employees
Revenue 2025
DKK 2,4M
-21% vs 2024
EBITDA margin
32.6%
-48% vs 2024
Equity ratio
49.1%
Financial strength
Net profit 2025
DKK 586K
-49% vs 2024
| Revenue | DKK 2,4M | -21% |
| EBITDA | DKK 776K | -48% |
| Net profit | DKK 586K | -49% |
| Total assets | DKK 7,8M | +26% |
| Equity | DKK 3,8M | +10% |
| Employees | 6 | — |
Legal name
Pharmovital ApS
CVR number
27206506
Legal form
Anpartsselskab
NACE code
4638 · Wholesale of other food
Founded
16. juni 2003
Share capital
DKK 100.000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør
Company purpose
Selskabets formål er at drive produktion, handel og al virksomhed som efter direktionens skøn er beslægtet hermed.
Address
Rosenkæret 11B
Phone
+4525328499
Email
ek@pharmovital.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 1.536 | 1.739 | 1.809 | 1.850 | 1.799 | 1.184 | 2.329 | 1.816 | 1.073 | 2.524 | 2.909 | 3.018 | 2.380 |
| Staff expenses | -0 | -893 | -1.222 | -1.180 | -1.419 | -1.707 | -1.693 | -1.374 | -1.485 | -1.723 | -1.672 | -1.554 | -1.517 | -1.603 |
| EBITDA | 22 | 643 | 517 | 628 | 432 | 92 | -320 | 955 | 331 | -650 | 822 | 1.355 | 1.501 | 776 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -16 | -38 | -57 | -38 | -6 | -0 | -0 |
| EBIT | 22 | 643 | 517 | 628 | 432 | 92 | -321 | 939 | 293 | -707 | 784 | 1.349 | 1.501 | 776 |
| Net financials | 0 | -4 | 1.328 | -14 | -31 | -18 | -32 | -16 | 54 | -84 | -56 | -28 | -19 | -18 |
| Profit before tax | 22 | 639 | -811 | 614 | 401 | 74 | -353 | 922 | 347 | -791 | 728 | 1.321 | 1.482 | 758 |
| Tax | -0 | 158 | 131 | 133 | 91 | 21 | -0 | 115 | 97 | -19 | 9 | 291 | 329 | 172 |
| Net profit | 22 | 481 | -942 | 481 | 310 | 53 | -353 | 807 | 251 | -772 | 719 | 1.030 | 1.153 | 586 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.454 | 3.216 | 2.713 | 3.368 | 2.966 | 3.060 | 2.995 | 4.405 | 4.273 | 5.444 | 6.471 | 6.428 | 6.185 | 7.785 |
| Equity | 329 | 1.278 | 336 | 818 | 1.128 | 1.181 | 828 | 1.635 | 1.685 | 1.931 | 2.349 | 2.579 | 3.482 | 3.818 |
| Long-term debt | 1.110 | 1.110 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 16 | 828 | 2.377 | 2.550 | 1.839 | 1.879 | 2.168 | 2.770 | 2.571 | 3.513 | 4.122 | 3.849 | 2.702 | 3.966 |
| Total debt | 1.126 | 1.938 | 2.377 | 2.550 | 1.839 | 1.879 | 2.168 | 2.770 | 2.571 | 3.513 | 4.122 | 3.849 | 2.702 | 3.966 |
EBITDA margin
32.6%
This company
15.8%
Market median
+106% vs market
20122025
Equity ratio
49.1%
This company
38.2%
Market median
+29% vs market
20122025
Return on equity
15.4%
This company
18.4%
Market median
+16% vs market
20122025
Net profit margin
24.6%
This company
8.1%
Market median
+204% vs market
20122025
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20122025
Debt / equity
1.04×
This company
0.62×
Market median
-68% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AH Chief Executive Officer | Chief Executive Officer | 2003 | — | — |
EK Management | Management | 2003 | — | — |
KK Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2003 | — | — | |
| Chairman | 2003 | — | — | |
| Chairman | 2003 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Kr. Krogh Holding ApS | Company | 50.0% | 50.0% | 2024 |
Eskro Holding ApS | Company | 50.0% | 50.0% | 2024 |
KROFI ApS | Company | 100.0% | 100.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Eskro Holding ApS
Pharmovital ApS Board members of Pharmovital ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Annemette Heller | Chief Executive Officer | 0 companies |
| Eskil Krogh | Management | 0 companies |
| Kristian Krogh | Chief Executive Officer | 0 companies |
| Hans Ole Svendsen | Board of Directors | 0 companies |
| Steffen Møller | Chairman | 0 companies |
| Kim Madsen | Chairman | 0 companies |